TY - JOUR
T1 - Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions
AU - Striegler, Christin
AU - Schumacher, Matthias
AU - Effenberg, Christiane
AU - Mueller, Martin
AU - Seckinger, Anja
AU - Schnettler, Reinhard
AU - Voit, Brigitte
AU - Hose, Dirk
AU - Gelinsky, Michael
AU - Appelhans, Dietmar
PY - 2015
Y1 - 2015
N2 - Establishment of drug delivery system (DDS) in bone substitute materials for local treatment of bone defects still requires ambitious solutions for a retarded drug release. We present two novel DDS, a weakly cationic dendritic glycopolymer and a cationic polyelectrolyte complex, composed of dendritic glycopolymer and cellulose sulfate, for the proteasome inhibitor bortezomib. Both DDS are able to induce short-term retarded release of bortezomib from calcium phosphate bone cement in comparison to a burst-release of the drug from bone cement alone. Different release parameters have been evaluated to get a first insight into the release mechanism from bone cements. In addition, biocompatibility of the calcium phosphate cement, modified with the new DDS was investigated using human mesenchymal stromal cells.
AB - Establishment of drug delivery system (DDS) in bone substitute materials for local treatment of bone defects still requires ambitious solutions for a retarded drug release. We present two novel DDS, a weakly cationic dendritic glycopolymer and a cationic polyelectrolyte complex, composed of dendritic glycopolymer and cellulose sulfate, for the proteasome inhibitor bortezomib. Both DDS are able to induce short-term retarded release of bortezomib from calcium phosphate bone cement in comparison to a burst-release of the drug from bone cement alone. Different release parameters have been evaluated to get a first insight into the release mechanism from bone cements. In addition, biocompatibility of the calcium phosphate cement, modified with the new DDS was investigated using human mesenchymal stromal cells.
U2 - 10.1002/MABI.201500085
DO - 10.1002/MABI.201500085
M3 - Article
SN - 1616-5187
VL - 15
SP - 1283
EP - 1295
JO - Macromolecular Bioscience
JF - Macromolecular Bioscience
IS - 9
ER -